Tatiana Prowell: … how much she has given to the lung cancer community

Tatiana Prowell shared a post by Ivy Elkins, Co-Founder of EGFR Resisters, on X/Twitter, adding:

”Medicine is the best job and science will win. Anyone who has ever had the privilege of working with Ivy Elkins knows how much she has given to the lung cancer patient advocacy community in those years. Congrats on the milestone, friend!”

Quoting Ivy Elkins’s post:

”10 years ago on 12/26, I was diagnosed with stage IV EGFR+ lung cancer. I’m still here thanks to research and making memories with my family!”

Source: Tatiana Prowell/X and Ivy Elkins/X

Tatiana M. Prowell is an Associate Professor of Oncology in the Division of Women’s Malignancies at the Johns Hopkins Kimmel Comprehensive Cancer Center and Breast Cancer Scientific Liaison to the U.S. Food and Drug Administration. She was the principal architect of FDA’s policy on accelerated approval using pathological complete response as a novel regulatory endpoint in the neoadjuvant high-risk breast cancer setting, and a member of the Biden Cancer Moonshot Blue Ribbon Panel Cancer Immunology Working Group.

A frequent public speaker, she is a three-time recipient of FDA’s Excellence in Communication Award. She is a past Giants of Cancer Care Award finalist, the recipient of the 2019 John and Samuel Bard Medal in Science or Medicine, and the recipient of a 2020 Webby Special Achievement Award for her effective use of social media during the pandemic. A passionate medical educator and mentor, she was Chair of the 2020 ASCO Annual Meeting Education Committee.